{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:50:49Z","timestamp":1785790249880,"version":"3.56.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00813-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:33:45Z","timestamp":1785742425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting"],"prefix":"10.1186","volume":"15","author":[{"given":"Tiantian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"Supplement 1","key":"813_CR1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood-2025-1024","volume":"146","author":"V Gupta","year":"2025","unstructured":"Gupta V, Mascarenhas J, Ali H, Ross D, Yacoub A, Jain T, et al. Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia. Blood. 2025;146(Supplement 1):1024.","journal-title":"Blood"},{"issue":"Supplement 1","key":"813_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/blood-2025-484","volume":"146","author":"J Mascarenhas","year":"2025","unstructured":"Mascarenhas J, Al-Ali HK, Gupta V, Ali H, Palandri F, Passamonti PF, et al. Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies. Blood. 2025;146(Supplement 1):484.","journal-title":"Blood"},{"key":"813_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2025-71","volume":"146","author":"B Psaila","year":"2025","unstructured":"Psaila B, Nangalia J, Gotlib J, Harrison C, Mascarenhas J, Crowgey E, et al. Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells. Blood. 2025;146:71.","journal-title":"Blood"},{"issue":"6","key":"813_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"S Parampalli Yajnanarayana","year":"2015","unstructured":"Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J, et al. JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169(6):824\u201333.","journal-title":"Br J Haematol"},{"issue":"8","key":"813_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, et al. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024;390(8):723\u201335.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"813_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2025-81","volume":"146","author":"A Kuykendall","year":"2025","unstructured":"Kuykendall A, Bankar A, Pettit K, Shatzel J, Lucchesi A, Garc\u00eda Guti\u00e9rrez V, et al. Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study. Blood. 2025;146(Supplement 1):81.","journal-title":"Blood"},{"issue":"Supplement 1","key":"813_CR7","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1182\/blood-2025-3810","volume":"146","author":"N Pemmaraju","year":"2025","unstructured":"Pemmaraju N, Kuykendall A, Ritchie E, Gotlib J, Palmer J, Gerds A, et al. Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study. Blood. 2025;146(Supplement 1):3810.","journal-title":"Blood"},{"key":"813_CR8","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1182\/blood-2025-5587","volume":"146","author":"J Shatzel","year":"2025","unstructured":"Shatzel J, Kuykendall A, Bankar A, Pemmaraju N, Pettit K, Lucchesi A, et al. Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure. Blood. 2025;146:5587.","journal-title":"Blood"},{"issue":"Supplement 1","key":"813_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1182\/blood-2025-910","volume":"146","author":"R Rampal","year":"2025","unstructured":"Rampal R, Mascarenhas J, Grosicki S, Chraniuk D, Abruzzese E, Bose P, et al. Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor\u2013Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study. Blood. 2025;146(Supplement 1):910.","journal-title":"Blood"},{"key":"813_CR10","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1182\/blood-2025-7341","volume":"146","author":"S Tan","year":"2025","unstructured":"Tan S, Li Y, Cao Y, Sun W, Hui W. Efficacy and safety of ruxolitinib-based combination therapy in the patients with myelofibrosis (MF): A systematic review and meta-analysis. Blood. 2025;146:7341.","journal-title":"Blood"},{"issue":"Supplement 1","key":"813_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2025-82","volume":"146","author":"J Palmer","year":"2025","unstructured":"Palmer J, How J, Bose P, Vachhani P, Mead A, Sillar J, et al. Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial. Blood. 2025;146(Supplement 1):82.","journal-title":"Blood"},{"issue":"Supplement 1","key":"813_CR12","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood-2025-2033","volume":"146","author":"D Ross","year":"2025","unstructured":"Ross D, Wilson A, Cochrane T, Stevenson W, Liang J, Brociner M, et al. Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study. Blood. 2025;146(Supplement 1):2033.","journal-title":"Blood"},{"issue":"Supplement 1","key":"813_CR13","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1182\/blood-2025-2052","volume":"146","author":"J Mascarenhas","year":"2025","unstructured":"Mascarenhas J, Kuykendall A, Bradley T, Scott B, Yimer H, Yang Y, et al. Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis. Blood. 2025;146(Supplement 1):2052.","journal-title":"Blood"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00813-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:03:37Z","timestamp":1785787417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00813-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00813-0","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"69"}}